Kazia Therapeutics Limited Regains Nasdaq Compliance

Kazia Therapeutics Limited has received notification from Nasdaq that it has regained compliance with the minimum $2.5 million stockholders' equity requirement, fulfilling the alternative to the Market Value of Listed Securities (MVLS) requirement. The company had previously been informed of non-compliance with the $35 million MVLS requirement by November 10, 2025. Kazia had requested a hearing, scheduled for January 8, 2026. However, with the regained compliance in stockholders' equity, the hearing has been cancelled, and Nasdaq will continue the listing of the company's ADSs on The Nasdaq Capital Market. This information is incorporated into the company's registration statement on Form F-3.